Avalo Therapeutics to Participate in Upcoming Investor Conferences

About this update from Avalo Therapeutics, Inc.

[{"type":"image","alt":"Avalo Therapeutics","displaySize":"","headline":null,"caption":"Avalo Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":161,"url":"https://media.zenfs.com/en/globenewswire.com/64359ff9edc0e46c29be0915b2a0157e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ANi8XHp5jL2i.Q7JsBSgWw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyNTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/64359ff9edc0e46c29be0915b2a0157e","width":300,"height":161}},"lazy":false},{"type":"text","content":"WAYNE, Pa., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced that management will participate in the following investor conferences:","length":309,"tagName":"p"},{"type":"text","content":"Guggenheim Emerging Outlook: Biotech Summit 2026Fireside ChatFebruary 11, 2026, at 10:00 am ET","length":96,"tagName":"p"},{"type":"text","content":"Oppenheimer 36th Annual Healthcare Life Sciences ConferenceFireside ChatFebruary 25, 2026, at 10:00 am ET","length":107,"tagName":"p"},{"type":"text","content":"Live webcasts and replays, when available, can be found under "News / Events" in the Investors section of the Avalo Therapeutics website at https://ir.avalotx.com. The archived webcast will be available for replay for at least 30 days.","length":255,"tagName":"p"},{"type":"text","content":"About Avalo Therapeutics","length":24,"tagName":"p"},{"type":"text","content":"Avalo Therapeutics is a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases. Our lead asset, AVTX-009, is in a Phase 2 clinical trial for hidradenitis suppurativa (HS). We’re also exploring additional opportunities to make an impact in prevalent indications that have significant remaining unmet needs. For more information about Avalo, please visit www.avalotx.com.","length":451,"tagName":"p"},{"type":"text","content":"About AVTX-009 ","length":14,"tagName":"p"},{"type":"text","content":"AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. IL-1β is a pro-inflammatory cytokine that plays a central ...

More updates from Avalo Therapeutics, Inc.